Genotype-specific effects of elamipretide in patients with primary mitochondrial myopathy: a post hoc analysis of the MMPOWER-3 trial

Amel Karaa(Istituto delle Scienze Neurologiche di Bologna), Robert D. S. Pitceathly(National Hospital for Neurology and Neurosurgery), Gráinne S. Gorman(Wellcome Centre for Mitochondrial Research), Jeffrey S. Finman(Jupiter Medical Center), Fernando Scaglia(Baylor College of Medicine), Amy B. Goldstein(Northwell Health), Mark A. Tarnopolsky(McMaster University), Mary Kay Koenig, Alana Sullivan(Stealth BioTherapeutics (United States)), Jerry Vockley(Pittsburgh Public Schools), Serenella Servidei(Università Cattolica del Sacro Cuore), Thomas Klopstock(Ludwig-Maximilians-Universität München), Cornelia Kornblum(University of Bonn), Sumit Parikh(Cleveland Clinic), Anna Lehman(University of British Columbia), Russell P. Saneto(Seattle Children's Hospital), Anthony Abbruscato(Stealth BioTherapeutics (United States)), Costanza Lamperti(West Virginia University), Marni J. Falk(Children's Hospital of Philadelphia), Enrico Bertini(Bambino Gesù Children's Hospital), Valério Carelli(Istituto delle Scienze Neurologiche di Bologna), Johan L.K. Van Hove(Children's Hospital Colorado), Mária Judit Molnár(Istituto delle Scienze Neurologiche di Bologna), António Toscano(University of Messina), David A. Brown(Istituto delle Scienze Neurologiche di Bologna), James A. Shiffer(Istituto delle Scienze Neurologiche di Bologna), Nicola Longo(Center for Human Genetics), Michio Hirano(Columbia University Irving Medical Center), Michelango Mancuso(Istituto delle Scienze Neurologiche di Bologna), H. Phan(Rare Disease Therapeutics (United States)), Bruce M. Cohen(Harvard University), Richard Haas(University of California San Diego), John Vissing(University of Copenhagen), Gregory M. Ennes(Stanford University)
Orphanet Journal of Rare Diseases
November 21, 2024
Cited by 11


Related Papers